January 17, 2014 / 7:32 AM / in 4 years

Shire disposes of diabetic leg ulcer treatment Dermagraft

LONDON, Jan 17 (Reuters) - British pharmaceutical firm Shire said on Friday it had agreed to divest Dermagraft, a bio-engineered skin substitute used to treat diabetic foot ulcers, to Organogenesis for no upfront payment.

Shire acquired Dermagraft in June 2011 through its $750 million purchase of privately held Advanced BioHealing, but the treatment failed to realise its development hopes when a late-stage trial to treat venous leg ulcers disappointed later that year.

The company said on Friday that the prospects for the product had reduced significantly following a recent Medicare ruling on reimbursement.

It said it would receive no upfront payment from Canton, Massachusetts-based Organogenesis for the assets, but it would be entitled to receive up to $300 million cash in total milestone payments if it meets sales targets.

It said it would record a loss on disposal of approximately $650 million in the fourth quarter of 2013, which will be excluded from Non GAAP earnings.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below